Tirzepatide for Obesity Treatment and Diabetes Prevention (SURMOUNT-1, 3-Year Analysis)

Plain-language summary

This phase 3, double-blind, randomized controlled trial followed 2,539 participants with obesity — including 1,032 with prediabetes — for three years, finding that tirzepatide produced substantial and sustained reductions in body weight compared to placebo. Notably, participants with prediabetes who received tirzepatide showed a markedly lower risk of progressing to type 2 diabetes. These long-term results from the SURMOUNT-1 trial reinforce the dual GLP-1/GIP receptor agonist's potential role in both weight management and metabolic disease prevention.